ArticleThe oncologist2026

Perioperative enfortumab vedotin plus pembrolizumab in muscle-invasive bladder cancer: unprecedented outcomes from KEYNOTE-B15.

Sarah Azari et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.